

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8318860

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
DICERNA PHARMACEUTICALS, INC.	12/07/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NOVO NORDISK A/S
<b>Street Address:</b>	NOVO ALLE 1
<b>City:</b>	BAGSVAERD
<b>State/Country:</b>	DENMARK
<b>Postal Code:</b>	DK-2880
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	18213289
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(609)987-5440
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	609-987-5800
<b>Email:</b>	nnipatent@novonordisk.com
<b>Correspondent Name:</b>	NOVO NORDISK INC.
<b>Address Line 1:</b>	800 SCUDDERS MILL ROAD
<b>Address Line 4:</b>	PLAINSBORO, NEW JERSEY 08536
<b>ATTORNEY DOCKET NUMBER:</b>	210088US02
<b>NAME OF SUBMITTER:</b>	PRIYA PATEL
<b>SIGNATURE:</b>	/Priya Patel/
<b>DATE SIGNED:</b>	12/08/2023
<b>Total Attachments: 1</b>	
source=210088US02_Signed_SplitAssignment#page1.tif	

## ASSIGNMENT

WHEREAS, Dicerna Pharmaceuticals, Inc., a corporation organized under the laws of United States of America, located at 75 Hayden Avenue, Lexington, MA 02421 (hereinafter ASSIGNOR) is the current owner of the entire right, title to, and interest in U.S. Application No. 18/213,289 ("the' 289 application"), as evidenced by an assignment recorded in the U.S. Patent & Trademark Office at Reel 065536, Frames 0911, and now wishes to transfer an **undivided one-half** right, title to, and interest in the invention as a whole as set forth in the '289 application to Novo Nordisk A/S.

WHEREAS, Novo Nordisk A/S, located at Novo Alle 1, DK-2880 Bagsvaerd, Denmark (hereinafter ASSIGNEE) is desirous of acquiring an **undivided one-half** right, title to, and interest in, along with Dicerna Pharmaceuticals, Inc., the invention as a whole as set forth in the '289 application.

NOW, THEREFORE, ASSIGNOR hereby assigns to (i) ASSIGNOR and (ii) ASSIGNEE, its successors, legal representatives, or assigns, an **undivided one-half** right, title to, and interest in the invention as a whole as set forth in the '289 application and any continuations, continuations in-part, and/or divisions thereof, any patents arising therefrom, and any extensions, reissues, and/or reexamined patents thereof or related thereto, and all rights in any patent applications, patents, and/or similar legal instruments that may claim a priority right that is predicated upon or arises from any such applications or patents in any country.

Date: 12/7/23

Dicerna Pharmaceuticals, Inc.

By: \_\_\_\_\_



Name: Forrester Liddle

Title: Head of IP & Legal, US R&D